Pest experts reveal the reasons mosquitoes bite certain people — and you'll be surprised
Wether you're at home or away on vacation, getting rid of mosquitoes is frustrating to say the least. At just 2 to 4 mm in size, these blood-sucking pests can bite you and leave behind an itchy or raised rash which can be irritating for days.
But, if you're prone to getting mosquito bites more than your partner or family members, you might be wondering why.
According to pest controllers, certain people are more enticing for mosquitoes to feast on than others — and this all depends on several factors.
Luckily, we've got the experts at hand to answer all your questions, and to reveal the reasons mosquitoes will only bite certain people.
Believe it or not, mosquitoes are attracted to a particular body size of a person. This is down to the amount of carbon dioxide exhaled, which attracts mosquitoes.
"First, body factors do affect the menu for mosquitoes, and size plays into it," states Allan Bossel, Operations Expert at Bed Bug Exterminator.
Get instant access to breaking news, the hottest reviews, great deals and helpful tips.
"Some people give off more carbon dioxide when they breathe, and that is the main chemical that attracts mosquitoes like magnets. So if you are taller or heavier, your lungs pump out more of it."
Whether we're dripping in sweat in a heatwave, or have just finished a daily jog, workout or physical activity, it's probably best to jump in the shower straight away.
"Sweat plays a role," states Bossel. "The lactic acid and ammonia found in sweat are two of the main attractants for mosquitoes. If you just went for a 30-minute jog and skipped a rinse, you are basically a walking mosquito lure.
While daytime biting mosquitoes are increasing in range, the real pressure comes from dusk until dawn. The best way to help prevent bites is to plan ahead and be prepared with a repellent solution of your choosing that fits the occasion.
If you are stationary around the table, on the porch, patio or deck, a spatial repellent like Thermacell is great to use. For those on the go, personal DEET-based sprays offer great protection."
It's important to note that only female mosquitoes feed on blood and only to breed
What's more, you're only likely to get bitten by female mosquitoes, as they feed on blood to breed.
"Mosquitoes have evolved to really be able to zero in on their targets," adds Adam Goess, Executive Director of Innovation & Insights at Thermacell Repellents, Inc. and in-house Bug Expert.
"It's important to note that only female mosquitoes feed on blood and only to breed. They are attracted to CO2 and the lactic acid on our skin. Oftentimes outdoor activities will cause us to sweat a little more or breathe a little harder, alerting mosquitoes to our presence."
Another interesting reason why mosquitoes bite certain people is dependent on their blood type.
"With blood type, people with Type O blood are found to be bitten more frequently than those with Type A or B" states David Price, Associate Certified Entomologist and Vice President, Strategic Growth, Mosquito Joe.
"Mosquitoes can detect blood type in markers in skin secretions, although any blood type can be bitten."
So, if you are a blood Type O, what are the best ways to repel buzzing mosquitoes?
"Most natural solutions work by masking the odors that mosquitoes key in on (CO2, lactic acid). Solutions like vanilla extract, lavender, peppermint, eucalyptus etc., must be applied in high concentrations around every 30 minutes to see any noticeable effectiveness," advises Goess.
This pure peppermint oil is paraben free, and provides a fresh scent. Versatile to use in aromatherapy, or in an oil or reed diffuser. And while the fragrance is pleasant to our senses, it is also known to be a natural mosquito and pest repellent.
Luckily, there are plenty of ways to get rid of mosquitoes in your home and your yard, and you can even make your own non-toxic mosquito trap in just a few easy steps.
Essential oils such as peppermint, lavender or citronella are also great, natural mosquito repellents.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
5 hours ago
- Business Wire
Align Technology Announces Invisalign ® System With Mandibular Advancement Featuring Occlusal Blocks for Class II Skeletal and Dental Correction
MUMBAI, INDIA--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced commercial availability in India of the Invisalign System with mandibular advancement featuring occlusal blocks designed specifically to address Class II skeletal and dental correction by simultaneously advancing the mandible while aligning the teeth. This innovative solution is Align's first clear aligner product with integrated solid occlusal blocks that is designed to deliver predictable mandibular advancement. Invisalign occlusal blocks provide durability, improve engagement, and enable vertical opening to offer earlier advancement of the mandible in cases like skeletal Class II with deep bite to improve treatment efficiency. The Invisalign System with mandibular advancement featuring occlusal blocks is the latest clinical innovation that expands Align's Class II treatment portfolio for growing patients by offering practitioners a comprehensive solution for treating growing patients with Class II malocclusions caused by mandibular retrusion. Class II malocclusion is one of the most common orthodontic problems, characterized by a discrepancy in jaw alignment where the lower jaw (mandible) is positioned too far back relative to the upper jaw (maxilla) and represents approximately 30-45% of malocclusions globally. This condition can lead to functional, aesthetic, and other challenges for patients if left untreated. The Invisalign System with mandibular advancement featuring occlusal blocks is primarily intended for growing patients in the late mixed or early permanent dentition stages (ages 10-16), who are still experiencing growth. By leveraging the natural growth potential during pre-adolescence and adolescence, the Invisalign System with mandibular advancement featuring occlusal blocks facilitates effective correction of Class II malocclusions, helping to improve occlusal relationships, enhance facial aesthetics, and provide long-term functional benefits, including: Efficient treatment. Minimizes the need for multiple appliances to treat conditions including severe deep bite. Treats Class II malocclusions while simultaneously aligning the teeth in a single, efficient process. Invisalign occlusal blocks are solid with laser welding, which ensures structural rigidity and durability throughout the treatment, to minimize crushing. The solid occlusal blocks allow for vertical opening and enables the Mandibular Advancement (MA) phase to begin sooner for Class ll deep bite cases or Class II div 2 patients who many times would have needed a pre-MA phase. Some crossbite cases may still need pre-MA. Elevated patient comfort, (1) and compliance (2). Made from patented SmartTrack™ material, which is predictable and more comfortable (1). Studies show that patient discomfort with functional appliances affects patient compliance with the prescribed wear time and could lead to unsatisfactory outcomes (2). Predictable tooth movement. Attachments are allowed on the teeth under the blocks to facilitate leveling and other movement or to help prevent unwanted movements (3). By combining SmartTrack™ material, SmartForce™ features, and SmartStage™ technology, it also allows for more predictable tooth movement (1). 'The Invisalign System with mandibular advancement featuring occlusal blocks reflects Align's continued commitment to expanding the capabilities of the Invisalign System, enabling doctors to treat a wider range of malocclusions with precision and efficiency, and helps to continue to advance clear aligners as the standard of care in digital orthodontics,' said Sreelakshmi Kolli, Align Technology executive vice president, chief product and digital officer. 'This latest innovation demonstrates our significant investment in delivering digital orthodontic solutions to growing patients that empower doctors to achieve predictable outcomes while enhancing the patient experience.' 'The Invisalign System with mandibular advancement featuring occlusal blocks represents a breakthrough in Class II treatment with clear aligners by allowing doctors to simultaneously address dental and skeletal discrepancies in a more predictable and efficient manner,' said Dr. Mitra Derakhshan, Align Technology executive vice president, chief clinical officer, global treatment planning and clinical services. 'The integration of occlusal blocks enhances mandibular engagement as well as provides bite opening making this a versatile solution for different Class II malocclusion including deep bite or div 2. The Invisalign System with mandibular advancement featuring occlusal blocks, gives doctors and patients a better option for Class II correction in growing patients while simultaneously straightening their teeth, including more options for feature placement, such as attachments on teeth underneath the blocks (3).' 'Treatment outcomes with the Invisalign System with mandibular advancement featuring occlusal blocks are on par with traditional Clark Twin Blocks,' said an orthodontist practicing in New Zealand who has treated 50 patients to date. 'In addition, the enhanced comfort of the Invisalign occlusal blocks increases predictability-- because comfort leads to patient compliance–and compliance leads to better outcomes.' 'Class II correction in growing patients is smooth sailing with the Invisalign System with mandibular advancement featuring occlusal blocks,' said an orthodontist practicing in Australia. 'The patients instinctively know how to bite, and it works so I don't see any crushed blocks. The fact that we see no crushing issues means patients can keep moving through treatment without any delays or additional appointments.' 'I'm very happy with the new Invisalign System with mandibular advancement featuring occlusal blocks design,' said a Canada-based orthodontist. 'Patients can bite down easily without risk of damaging or distorting the blocks, and the mandibular advanced position is easy to maintain. My young patients have found it very easy to transition to this appliance with minimal discomfort, and compliance has been a breeze." 'The Invisalign System with mandibular advancement featuring occlusal blocks provides the ideal block engagement that helps hold the mandible in the proper position for patients that also have mandibular asymmetry. This allows for more efficient corrections when desired,' said an orthodontist based in Canada. 'Invisalign system with mandibular advancement featuring occlusal blocks remove the need for auxiliary elastics, which removes one more obstacle for patients. In addition, the trays do not require palatal coverage like traditional removable Class ll correctors, and there are no changes in the insertion and removal process of the aligners. My younger patients love the ability to remove the aligners for eating, which is not commonly an option for patients that require fixed Class ll correctors or elastics.' The Invisalign System with mandibular advancement featuring occlusal blocks is now commercially available to Invisalign-trained doctors in Australia, New Zealand, Japan, Hong Kong and India, and is expected to be introduced in additional APAC markets later in 2025. Along with the Invisalign® Palatal Expander System, Invisalign First™ and Invisalign System with mandibular advancement featuring occlusal blocks, this latest innovation supports the commitment to establishing a unique and differentiated portfolio that supports growing patients throughout their continuum of care. For more information about the Invisalign System with mandibular advancement featuring occlusal blocks, or to schedule a training session, please visit or contact your local Align Technology representative. 1. Compared to Invisalign aligners previously made from single-layer (EX30) material. 2. Studies show that patient discomfort with functional appliances affect patient compliance with the prescribed wear time and could lead to unsatisfactory outcomes. 3. In some cases, attachments may be removed on teeth under occlusal blocks due to interferences with other features. Expand About Align Technology, Inc. Align Technology designs and manufactures the Invisalign® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 281.4 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat approximately 20.1 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit for more information. For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit For additional information about the iTero digital scanning system, please visit For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit Invisalign, iTero, exocad, Align, Align Digital Platform, and iTero Lumina are trademarks of Align Technology, Inc.
Business Upturn
8 hours ago
- Business Upturn
Da Vinci's Vitruvian Man Encodes the Blueprint of Human Evolution, Says London Dentist
Photo Courtesy of Rory Mac Sweeney LONDON, July 14, 2025 (GLOBE NEWSWIRE) — A London-based dental surgeon and researcher, Dr. Rory Mac Sweeney of Precision Endodontics, has ignited international interest with a provocative reinterpretation of Leonardo da Vinci's Vitruvian Man. His newly published research suggests the Renaissance masterpiece encodes a precise geometric ratio that reflects the biomechanical endpoint of human evolution. Dr. Mac Sweeney's theory, published in the Journal of Mathematics and the Arts, identifies a hidden equilateral triangle embedded in Vitruvian Man. He connects this geometry to Bonwill's Triangle—a fundamental dental structure first described in the 19th century, which governs optimal jaw alignment and function. According to Mac Sweeney, this triangular structure appears throughout the body and is mathematically anchored by the ratio √8/3, or approximately 1.633. 'Leonardo's drawing isn't just a study in proportion—it's a map of tension,' said Dr. Mac Sweeney. 'The 1.633 ratio appears in the jaw, the spine, and the skull. It reflects a state known as vector equilibrium, where structural tension and compression are perfectly balanced. I believe this marks the final step in the human journey toward full upright posture.' This ratio, derived from the geometry of the cuboctahedron, is widely recognized in biomechanics and architecture as a hallmark of tensegrity—the balance of forces within a stable form. Dr. Mac Sweeney contends that this geometry defines the Vitruvian Morphotype: a form that nature has converged on through evolutionary pressures—not because it is aesthetically pleasing, but because it is structurally optimal. 'Human evolution has been a long progression toward uprightness,' he explained. 'The 1.633 ratio may represent our evolutionary omega point—a structural threshold beyond which no further anatomical adaptation is needed to stand, move, and balance efficiently in gravity.' Mac Sweeney suggests that fossil evidence should reveal a slow convergence toward this geometric configuration, particularly in the jaw. He highlights the emergence of Class I occlusion in the fossil record—also known as the overbite/overjet 'step'—around 8,000 years ago as a key moment. While small variations remain, he argues that modern Homo sapiens are the first species to fully express this morphotype. 'It's like the hydrodynamic form of a dolphin,' he said. 'Nature solves gravity the way it solves water. Vitruvian Man is the first full sketch of what that solution looks like.' Dr. Mac Sweeney's theory is now attracting attention from experts in evolutionary biology, bioengineering, and anatomical design. He is currently conducting interviews, public talks, and media appearances to discuss what he calls the Vitruvian Ratio—and its broader implications for anthropology, architecture, and even consciousness. 'Leonardo, somehow, saw it coming,' Mac Sweeney added. 'Vitruvian Man may be the only anatomical diagram ever created that captures not just what a human is—but what a human is becoming.' About Dr. Rory Mac Sweeney: Dr. Mac Sweeney is a London-based endodontist and researcher known for his interdisciplinary work in dental anatomy, geometry, and human evolution. His work explores the convergence of structural biology and classical design, and he is the author of the book The Paradox of Lucid Dreaming. @luciddreamyoga Contact Information: Contact person: Dr. Rory Mac SweeneyCompany name: Precision EndodonticsWebsite: [ Press Contact: [email protected]
Business Wire
12 hours ago
- Business Wire
Simulations Plus Invests in Clinical Development Technology Company Nurocor
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) ('Simulations Plus'), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced an investment of $1 million in technology company Nurocor. Nurocor offers a cloud-based software platform designed to improve efficiency, reusability, governance, and automation for pharmaceutical companies through digitalization in the clinical development phase. Its solution significantly accelerates the typical clinical trial lifecycle, resulting in a reduction of the overall cost of the clinical development process. The investment was made as part of Simulations Plus' Corporate Development Initiative, launched in 2024 to support early-stage technology companies accelerating innovations within the pharmaceutical industry. 'We are pleased to support Nurocor in its mission to help clients leverage technology to bring drugs to market more rapidly,' said Shawn O'Connor, Chief Executive Officer of Simulations Plus. 'Their vision aligns with our own, and we see tremendous potential for clients to deploy our complementary solutions in clinical trial design, protocol development, and site competency and compliance. We believe our investment in Nurocor will deliver considerable and measurable value to clients and ultimately get much-needed treatments to patients faster.' 'We are excited to make this strategic investment through our Corporate Development Initiative,' said Will Frederick, Chief Financial Officer of Simulations Plus. 'This initiative is specifically designed to foster growth for early-stage companies, as well as identify potential partners and acquisition targets that complement our organic growth strategy and expand our total addressable market.' In 2024, the clinical trial technology and services sector—which encompasses digital tools and services—was estimated at $25.7 billion. It is projected to grow at a compound annual growth rate (CAGR) of 15.5% from 2025 to 2030, driven by the increasing adoption of digital health technologies and the growing demand for more efficient patient recruitment. 'We are thrilled to have the support of Simulations Plus as we enter our next stage of growth,' said Alex Lazar, Chief Executive Officer of Nurocor. 'The investment is a strong vote of confidence in our team and technology, and we look forward to partnering with them to help clients realize efficiencies through the optimization and automation of their clinical trials.' Interested parties can learn more about Simulations Plus' Corporate Development Initiative here. About Simulations Plus, Inc. With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | X | YouTube. Environmental, Social, and Governance (ESG) We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update. Forward-Looking Statements Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like 'believe,' 'will', 'can', 'believe', 'expect,' 'anticipate' and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: effectiveness of our new operational structure, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission. ###
